Early Dementia Screening
As the population of the world increases, there will be larger numbers of people with dementia and an emerging need for prompt diagnosis and treatment. Early dementia screening is the process by which a patient who might be in the prodromal phases of a dementing illness is determined as having, or n...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2016-01-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2075-4418/6/1/6 |
| _version_ | 1811298355592036352 |
|---|---|
| author | Peter K. Panegyres Renee Berry Jennifer Burchell |
| author_facet | Peter K. Panegyres Renee Berry Jennifer Burchell |
| author_sort | Peter K. Panegyres |
| collection | DOAJ |
| description | As the population of the world increases, there will be larger numbers of people with dementia and an emerging need for prompt diagnosis and treatment. Early dementia screening is the process by which a patient who might be in the prodromal phases of a dementing illness is determined as having, or not having, the hallmarks of a neurodegenerative condition. The concepts of mild cognitive impairment, or mild neurocognitive disorder, are useful in analyzing the patient in the prodromal phase of a dementing disease; however, the transformation to dementia may be as low as 10% per annum. The search for early dementia requires a comprehensive clinical evaluation, cognitive assessment, determination of functional status, corroborative history and imaging (including MRI, FDG-PET and maybe amyloid PET), cerebrospinal fluid (CSF) examination assaying Aβ1–42, T-τ and P-τ might also be helpful. Primary care physicians are fundamental in the screening process and are vital in initiating specialist investigation and treatment. Early dementia screening is especially important in an age where there is a search for disease modifying therapies, where there is mounting evidence that treatment, if given early, might influence the natural history—hence the need for cost-effective screening measures for early dementia. |
| first_indexed | 2024-04-13T06:18:16Z |
| format | Article |
| id | doaj.art-9f8478e16f59438f81b8add1e09506cc |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-04-13T06:18:16Z |
| publishDate | 2016-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-9f8478e16f59438f81b8add1e09506cc2022-12-22T02:58:44ZengMDPI AGDiagnostics2075-44182016-01-0161610.3390/diagnostics6010006diagnostics6010006Early Dementia ScreeningPeter K. Panegyres0Renee Berry1Jennifer Burchell2Neurodegenerative Disorders Research Pty Ltd, 4 Lawrence Avenue, West Perth 6005, Western Australia, AustraliaNeurodegenerative Disorders Research Pty Ltd, 4 Lawrence Avenue, West Perth 6005, Western Australia, AustraliaNeurodegenerative Disorders Research Pty Ltd, 4 Lawrence Avenue, West Perth 6005, Western Australia, AustraliaAs the population of the world increases, there will be larger numbers of people with dementia and an emerging need for prompt diagnosis and treatment. Early dementia screening is the process by which a patient who might be in the prodromal phases of a dementing illness is determined as having, or not having, the hallmarks of a neurodegenerative condition. The concepts of mild cognitive impairment, or mild neurocognitive disorder, are useful in analyzing the patient in the prodromal phase of a dementing disease; however, the transformation to dementia may be as low as 10% per annum. The search for early dementia requires a comprehensive clinical evaluation, cognitive assessment, determination of functional status, corroborative history and imaging (including MRI, FDG-PET and maybe amyloid PET), cerebrospinal fluid (CSF) examination assaying Aβ1–42, T-τ and P-τ might also be helpful. Primary care physicians are fundamental in the screening process and are vital in initiating specialist investigation and treatment. Early dementia screening is especially important in an age where there is a search for disease modifying therapies, where there is mounting evidence that treatment, if given early, might influence the natural history—hence the need for cost-effective screening measures for early dementia.http://www.mdpi.com/2075-4418/6/1/6Alzheimer’s diseasemild cognitive impairmentmild neurocognitive disorderclinical dementia rating scaleglobal deterioration scaleamnestic mild cognitive impairmentnon-amnestic mild cognitive impairmentcognitive testingtreatmentsSolanezumab |
| spellingShingle | Peter K. Panegyres Renee Berry Jennifer Burchell Early Dementia Screening Diagnostics Alzheimer’s disease mild cognitive impairment mild neurocognitive disorder clinical dementia rating scale global deterioration scale amnestic mild cognitive impairment non-amnestic mild cognitive impairment cognitive testing treatments Solanezumab |
| title | Early Dementia Screening |
| title_full | Early Dementia Screening |
| title_fullStr | Early Dementia Screening |
| title_full_unstemmed | Early Dementia Screening |
| title_short | Early Dementia Screening |
| title_sort | early dementia screening |
| topic | Alzheimer’s disease mild cognitive impairment mild neurocognitive disorder clinical dementia rating scale global deterioration scale amnestic mild cognitive impairment non-amnestic mild cognitive impairment cognitive testing treatments Solanezumab |
| url | http://www.mdpi.com/2075-4418/6/1/6 |
| work_keys_str_mv | AT peterkpanegyres earlydementiascreening AT reneeberry earlydementiascreening AT jenniferburchell earlydementiascreening |